The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics
Joint Authors
Sheau Chin, Lim
Ibrahim, Baharudin
Amin, Arwa M.
Azri Mohamed Noor, Dzul
SK Abdul Kader, Muhamad Ali
Kah Hay, Yuen
Source
Cardiology Research and Practice
Issue
Vol. 2017, Issue 2017 (31 Dec. 2017), pp.1-17, 17 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2017-03-21
Country of Publication
Egypt
No. of Pages
17
Main Subjects
Abstract EN
Dual antiplatelet therapy of aspirin and clopidogrel is pivotal for patients undergoing percutaneous coronary intervention.
However, the variable platelets reactivity response to clopidogrel may lead to outcome failure and recurrence of cardiovascular events.
Although many genetic and nongenetic factors are known, great portion of clopidogrel variable platelets reactivity remain unexplained which challenges the personalization of clopidogrel therapy.
Current methods for clopidogrel personalization include CYP2C19 genotyping, pharmacokinetics, and platelets function testing.
However, these methods lack precise prediction of clopidogrel outcome, often leading to insufficient prediction.
Pharmacometabolomics which is an approach to identify novel biomarkers of drug response or toxicity in biofluids has been investigated to predict drug response.
The advantage of pharmacometabolomics is that it does not only predict the response but also provide extensive information on the metabolic pathways implicated with the response.
Integrating pharmacogenetics with pharmacometabolomics can give insight on unknown genetic and nongenetic factors associated with the response.
This review aimed to review the literature on factors associated with the variable platelets reactivity response to clopidogrel, as well as appraising current methods for the personalization of clopidogrel therapy.
We also aimed to review the literature on using pharmacometabolomics approach to predict drug response, as well as discussing the plausibility of using it to predict clopidogrel outcome.
American Psychological Association (APA)
Amin, Arwa M.& Sheau Chin, Lim& Azri Mohamed Noor, Dzul& SK Abdul Kader, Muhamad Ali& Kah Hay, Yuen& Ibrahim, Baharudin. 2017. The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics. Cardiology Research and Practice،Vol. 2017, no. 2017, pp.1-17.
https://search.emarefa.net/detail/BIM-1150987
Modern Language Association (MLA)
Amin, Arwa M.…[et al.]. The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics. Cardiology Research and Practice No. 2017 (2017), pp.1-17.
https://search.emarefa.net/detail/BIM-1150987
American Medical Association (AMA)
Amin, Arwa M.& Sheau Chin, Lim& Azri Mohamed Noor, Dzul& SK Abdul Kader, Muhamad Ali& Kah Hay, Yuen& Ibrahim, Baharudin. The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics. Cardiology Research and Practice. 2017. Vol. 2017, no. 2017, pp.1-17.
https://search.emarefa.net/detail/BIM-1150987
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1150987